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	 HAT	 Chagas	disease	 The	leishmaniases
Principal disease forms  Early (hemolymphatic) stage,  Acute phase, indeterminant phase,  VL, MCL, CL
 or stages  late (CNS) stage  chronic phase (cardiac and 
   digestive forms)
Causative organisms T.b. gambiense, T.b. rhodesiense T. cruzi ∼21 Leishmania spp., e.g., L. donovani 
    (VL), L. braziliensis (MCL), L. major (CL)
Host cell/tissue Extracellular, in blood, lymph,  Intracellular, in cytoplasm of heart,  Intracellular, in phagolysosomes 
  cerebral spinal fluid, and   smooth muscle, gut, CNS, and   of macrophages
  intercellular spaces  adipose tissue cells
Vectors of medical  Tsetse flies (∼20 Glossina spp.)  Reduviid bugs (∼12/∼138  Phebotomine sandflies (∼70 spp.) 
 importance  (palpalis group, T.b. gambiense;   Triatominae spp.) (Triatoma,   (Phlebotomus spp. in Old World, 
  morsitans group, T.b. rhodesiense)  Rhodnius, and Panstrongylus spp.)  Lutzomyia spp. in New World)
Transmission Infected fly bite, congenital (rare),  Contamination by feces of infected  Infected fly bite
  blood transfusion (rare)  bugs (e.g., at bite site, in mucous 
   membranes, in food or drink), 
   blood transfusion, congenital, 
   organ transplantation (rare)
Geographic distribution Sub-Saharan Africa  South and Central America  South and Central America, Europe, Africa, 
  (∼20 countries)  (19 countries)  Asia (88 endemic countries)
Population at risk 50 million 100 million 350 million
Infected 70,000–80,000A 8–11 million 12 million
Health burden (DALYs) 1.5 million 0.7 million 2.1 million
Deaths (per annum) ∼30,000 14,000 51,000 (VL)
Prevention and control  Active surveillance of at-risk  Treatment of homes with residual  Surveillance and treatment of VL cases; 
 measures  populations, drug treatment of   insecticides, blood donor screening,  reservoir (dog) control (VL); 
  infected patients, tsetse fly traps,  	 drug treatment for acute, early   treatment of homes with residual 
  residual insecticides, sterile insect   indeterminate and congenital cases,   insecticides; insecticide-treated bed 
  technique, tsetse habitat    better housing (plastered walls and   nets, fabrics, and dog collars; live 
  destruction to inhibit reinvasion  metal roof replacing adobe-walled,   vaccination (“leishmanization,” CL)
   thatch-roofed dwellings)
Data obtained from refs. 132–138 and from http://www.who.int/neglected_diseases/diseases/en/. ACalculated based on the reported incidence in 2004 of 
∼18,000 cases identified from 3.3 million people under active surveillance, assuming 50 million at risk (8). DALY, disability-adjusted life year; MCL, muco-
cutaneous leishmaniasis.
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Life cycle of T. brucei. HAT is caused by infection 
with the T.b. rhodesiense or T.b. gambiense sub-
species. Over 20 species and subspecies of tsetse 
flies transmit these parasites, but only approxi-
mately 1 per 1,000 flies has the mature salivary 
gland infection that is necessary to transmit the par-
asite to humans. Trypanosomes enter the fly when 
it takes a meal of parasite-containing blood from 
an infected human or animal and, over a period of 
four weeks, undergo morphological and physiologi-
cal transformations in the alimentary tract and in 
the salivary glands, where they become infective. 
During a blood meal on the mammalian host, an 
infected tsetse fly injects parasites into skin tissue. 
The parasites pass via the lymphatic system into 
the bloodstream, which carries them throughout 
the body. The parasites continue to replicate by 
binary fission. In late-stage disease the parasites 
invade the CNS and reside in the cerebrospinal 
fluid and intercellular spaces. Figure modified with 
permission from Alexander J. da Silva and Melanie 
Moser, Centers for Disease Control Public Health 
Image Library.
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Life cycle of T. cruzi. Persistent infection with T. cruzi 
causes Chagas disease. The parasite is transmit-
ted to humans by infected blood-sucking Triato-
minae insects, which deposit trypomastigotes in 
their feces during feeding. The trypomastigotes 
enter the wound and invade nearby cells, within 
which they differentiate into intracellular amasti-
gotes that multiply by binary fission. The amasti-
gotes differentiate into trypomastigotes, which are 
released into the bloodstream and infect cells of 
multiple organs and tissues, including the heart, 
gut, CNS, smooth muscle, and adipose tissue and 
once again become amastigotes. The Triatominae 
insects become infected when they take a parasite-
containing blood meal from an infected human or 
animal. The trypomastigotes undergo morphologi-
cal and physiological transformations in the midgut 
of the vector and differentiate into infective trypo-
mastigotes in the hindgut. Image modified with 
permission from Alexander J. da Silva and Melanie 
Moser, Centers for Disease Control Public Health 
Image Library.
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Interventions: treatment, vector control,  



















































Life cycle of Leishmania spp. Infection with differ-
ent species of Leishmania causes distinct forms of 
leishmaniasis. For example, VL is caused by infec-
tion with either L. infantum or L. donovani; whereas 
CL is caused by infection with any one of several 
different Leishmania spp. Sandflies are the vectors 
that transmit the disease-causing protozoan para-
sites, injecting infective promastigotes when they 
take a blood meal. The parasites invade mamma-
lian macrophages by receptor-mediated endocy-
tosis, where they transform into amastigotes that 
multiply by binary fission. Sandflies become infect-
ed by ingesting infected cells when they take a 
meal of parasite-containing blood from an infected 
human or animal. The amastigotes transform into 
promastigotes and develop in the gut into meta-
cyclic promastigotes that are infective to humans. 
Figure modified with permission from Alexander J. 
da Silva and Melanie Moser, Centers for Disease 
Control Public Health Image Library.
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Acad. Sci. U. S. A. 90:775–779.
















rapid  immunochromatographic  test  with  the 
recombinant antigens K39 and K26 for the diag-
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